BioSpace News Archive

Centinel Spine®, LLC, (“the Company”) a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access, today announced the completion of the 250th procedure in the United States with its newly FDA-approved cervical total disc replacement system of prodisc solutions.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it has received pre-Investigational New Drug (PIND) application guidance from the U.S. Food and Drug Administration (FDA) for NobrXiol™.

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the successful completion of the safety phase and the enrollment of new patients into the expansion of the Phase 2 Clinical Trial Combining Precision Biologics NEO-201 monoclonal antibody with Pembrolizumab (Keytruda).

NewStem joins MSK Innovation Hub in collaboration to advance stem cell-based diagnostics that will increase cancer treatment efficacy

Grants to Americares, AMPATH Kenya, Amref, Sightsavers Inc. and USA for UNHCR

Medtronic plc today announced its continued inclusion in the Dow Jones Sustainability World Index (DJSI) as one of the world’s leading companies for sustainability.

Valbiotis announces the signature of a research partnership in intestinal microbiota with the MEDIS2 Unit from the Clermont Auvergne University on its active substances TOTUM•070 and TOTUM•448 against dyslipidemia and metabolic liver disease, partly financed by the French National Research Agency.

PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference.

Syndax Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 7,840,909 shares of its common stock at a price to the public of $22.00 per share.

PURE Bioscience, Inc., creator of the patented non-toxic silver dihydrogen citrate antimicrobial, reported financial results for the fiscal first quarter ended October 31, 2022.